1. Home
  2. AXGN vs ARQT Comparison

AXGN vs ARQT Comparison

Compare AXGN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

HOLD

Current Price

$42.83

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$21.19

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXGN
ARQT
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AXGN
ARQT
Price
$42.83
$21.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$42.33
$34.00
AVG Volume (30 Days)
687.9K
2.1M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
$225,208,000.00
$376,072,000.00
Revenue This Year
$20.57
$34.85
Revenue Next Year
$16.68
$29.39
P/E Ratio
N/A
N/A
Revenue Growth
20.21
91.34
52 Week Low
$9.22
$12.72
52 Week High
$45.83
$31.77

Technical Indicators

Market Signals
Indicator
AXGN
ARQT
Relative Strength Index (RSI) 60.10 48.26
Support Level $29.48 $21.12
Resistance Level $44.83 $21.95
Average True Range (ATR) 1.84 0.83
MACD -0.09 0.17
Stochastic Oscillator 74.86 73.40

Price Performance

Historical Comparison
AXGN
ARQT

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: